Bacitracin, Polyphloretini phosphate, neomycin sulfas - search results

United States - English - NLM (National Library of Medicine)

bacitracin injection, powder, for solution

xellia pharmaceuticals usa llc - bacitracin (unii: 58h6rwo52i) (bacitracin - unii:58h6rwo52i) - in accordance with the statements in the "warning box" the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it.

United States - English - NLM (National Library of Medicine)

bacitracin zinc and polymyxin b sulfate ointment

direct_rx - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin b sulfate. this product is contraindicated in those individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

bacitracin injection, powder, for solution

civica, inc. - bacitracin (unii: 58h6rwo52i) (bacitracin - unii:58h6rwo52i) - in accordance with the statements in the "warning box" the use of intramuscular bacitracin is limited to the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bacitracin and other antibacterial drugs, bacitracin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. this drug is contraindicated in those individuals with a history of previous hypersensitivity or toxic reaction to it.